Literature DB >> 35505157

LncRNA HDAC11-AS1 Suppresses Atherosclerosis by Inhibiting HDAC11-Mediated Adropin Histone Deacetylation.

Liang Li1, Wei Xie2.   

Abstract

LncRNA HDAC11-AS1 (HDAC11-AS1) is the natural antisense transcript of HDAC11, a key enzyme for DNA histone deacetylation. We evaluated the role of HDAC11-AS1 in atherosclerosis. In this research, we found that HDAC11-AS1 ameliorated blood lipid levels and atherosclerosis in high fat-dieted apoE-/- mice by regulating HDAC11 negatively. The change in blood lipid levels is related to the expression of LPL, which is enhanced by HDAC11-AS1 through regulating adropin histone deacetylation in vitro and in vivo. In conclusion, HDAC11-AS1 plays an anti-atherogenic role through adropin to induce LPL expressions, thereby enhancing TG metabolism. The results are valuable for the further development of HDAC11-AS1 and its clinical applications. It provides a new clinical therapeutic target for cardiovascular disease treatment.
© 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  Adropin; Atherosclerosis; Deacetylation; Lipoprotein lipase; Long non-coding RNAs

Year:  2022        PMID： 35505157     DOI： 10.1007/s12265-022-10248-7

Source DB:  PubMed          Journal:  J Cardiovasc Transl Res        ISSN： 1937-5387            Impact factor:   4.132


  40 in total

Review 1.  Atherosclerosis.

Authors:  Mohammed Shamim Rahman; Kevin Woollard
Journal:  Adv Exp Med Biol       Date:  2017       Impact factor: 2.622

Review 2.  Triglyceride lipases and atherosclerosis.

Authors:  Gunilla Olivecrona; Thomas Olivecrona
Journal:  Curr Opin Lipidol       Date:  2010-10       Impact factor: 4.776

3.  Adropin induction of lipoprotein lipase expression in tilapia hepatocytes.

Authors:  Anji Lian; Keqiang Wu; Tianqiang Liu; Nan Jiang; Quan Jiang
Journal:  J Mol Endocrinol       Date:  2015-10-13       Impact factor: 5.098

4.  Association of Body Mass Index With Lifetime Risk of Cardiovascular Disease and Compression of Morbidity.

Authors:  Sadiya S Khan; Hongyan Ning; John T Wilkins; Norrina Allen; Mercedes Carnethon; Jarett D Berry; Ranya N Sweis; Donald M Lloyd-Jones
Journal:  JAMA Cardiol       Date:  2018-04-01       Impact factor: 14.676

5.  Adropin is a novel regulator of endothelial function.

Authors:  Fina Lovren; Yi Pan; Adrian Quan; Krishna K Singh; Praphulla C Shukla; Milan Gupta; Mohammed Al-Omran; Hwee Teoh; Subodh Verma
Journal:  Circulation       Date:  2010-09-14       Impact factor: 29.690

Review 6.  From Lipids to Inflammation: New Approaches to Reducing Atherosclerotic Risk.

Authors:  Michael D Shapiro; Sergio Fazio
Journal:  Circ Res       Date:  2016-02-19       Impact factor: 17.367

7.  Apolipoprotein C-III inhibits triglyceride hydrolysis by GPIHBP1-bound LPL.

Authors:  Mikael Larsson; Christopher M Allan; Rachel S Jung; Patrick J Heizer; Anne P Beigneux; Stephen G Young; Loren G Fong
Journal:  J Lipid Res       Date:  2017-07-10       Impact factor: 5.922

Review 8.  Triglyceride Rich Lipoprotein -LPL-VLDL Receptor and Lp(a)-VLDL Receptor Pathways for Macrophage Foam Cell Formation.

Authors:  Sadao Takahashi
Journal:  J Atheroscler Thromb       Date:  2017-04-19       Impact factor: 4.928

Review 9.  Adropin- A Novel Biomarker of Heart Disease: A Systematic Review Article.

Authors:  Somaye Yosaee; Sepideh Soltani; Eghbal Sekhavati; Shima Jazayeri
Journal:  Iran J Public Health       Date:  2016-12       Impact factor: 1.429

10.  Adropin: An endocrine link between the biological clock and cholesterol homeostasis.

Authors:  Sarbani Ghoshal; Joseph R Stevens; Cyrielle Billon; Clemence Girardet; Sadichha Sitaula; Arthur S Leon; D C Rao; James S Skinner; Tuomo Rankinen; Claude Bouchard; Marinelle V Nuñez; Kimber L Stanhope; Deborah A Howatt; Alan Daugherty; Jinsong Zhang; Matthew Schuelke; Edward P Weiss; Alisha R Coffey; Brian J Bennett; Praveen Sethupathy; Thomas P Burris; Peter J Havel; Andrew A Butler
Journal:  Mol Metab       Date:  2017-12-30       Impact factor: 7.422
View more
  2 in total

1.  Adropin Inhibits Vascular Smooth Muscle Cell Osteogenic Differentiation to Alleviate Vascular Calcification via the JAK2/STAT3 Signaling Pathway.

Authors:  Li Wang; Fulu Jin; Peiyu Wang; Shiqiang Hou; Tao Jin; Xiansong Chang; Liangping Zhao
Journal:  Biomed Res Int       Date:  2022-07-27       Impact factor: 3.246

2.  Identification of novel cuproptosis-related lncRNA signatures to predict the prognosis and immune microenvironment of breast cancer patients.

Authors:  Zi-Rong Jiang; Lin-Hui Yang; Liang-Zi Jin; Li-Mu Yi; Ping-Ping Bing; Jun Zhou; Jia-Sheng Yang
Journal:  Front Oncol       Date:  2022-09-20       Impact factor: 5.738
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.